What to Know About This Obesity Drug Developer That Just Drew a New $7 Million Investment

On February 17, 2026, ACT Capital Management disclosed a new position in Viking Therapeutics (NASDAQ:VKTX), acquiring 206,100 shares worth $7.25 million. What happened According to an SEC filing dated February 17, 2026, ACT Capital Management established a new position in Viking Therapeutics (NASDAQ:VKTX), adding 206,100 shares. The position’s value at quarter-end stood at $7.25 million. What else to know This is a new position, representing 5.86% of the fund’s reportable assets under management as of ...